vs
Side-by-side financial comparison of READING INTERNATIONAL INC (RDI) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $50.3M, roughly 1.8× READING INTERNATIONAL INC). Vericel Corp runs the higher net margin — 25.0% vs -5.1%, a 30.1% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs -14.2%). Vericel Corp produced more free cash flow last quarter ($12.8M vs $4.1M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 5.6%).
The Reading Company was a Philadelphia-headquartered railroad that provided passenger and freight transport in eastern Pennsylvania and neighboring states from 1924 until its acquisition by Conrail in 1976.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
RDI vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $50.3M | $92.9M |
| Net Profit | $-2.6M | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | -1.9% | 24.1% |
| Net Margin | -5.1% | 25.0% |
| Revenue YoY | -14.2% | 23.3% |
| Net Profit YoY | -14.5% | 17.3% |
| EPS (diluted) | $-0.11 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $50.3M | $92.9M | ||
| Q3 25 | $52.2M | $67.5M | ||
| Q2 25 | $60.4M | $63.2M | ||
| Q1 25 | $40.2M | $52.6M | ||
| Q4 24 | $58.6M | $75.4M | ||
| Q3 24 | $60.1M | $57.9M | ||
| Q2 24 | $46.8M | $52.7M | ||
| Q1 24 | $45.1M | $51.3M |
| Q4 25 | $-2.6M | $23.2M | ||
| Q3 25 | $-4.2M | $5.1M | ||
| Q2 25 | $-2.7M | $-553.0K | ||
| Q1 25 | $-4.8M | $-11.2M | ||
| Q4 24 | $-2.2M | $19.8M | ||
| Q3 24 | $-7.0M | $-901.0K | ||
| Q2 24 | $-12.8M | $-4.7M | ||
| Q1 24 | $-13.2M | $-3.9M |
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 68.9% |
| Q4 25 | -1.9% | 24.1% | ||
| Q3 25 | -0.6% | 5.1% | ||
| Q2 25 | 4.8% | -3.2% | ||
| Q1 25 | -17.2% | -24.3% | ||
| Q4 24 | 2.6% | 24.5% | ||
| Q3 24 | -0.6% | -4.3% | ||
| Q2 24 | -16.4% | -11.5% | ||
| Q1 24 | -16.7% | -10.7% |
| Q4 25 | -5.1% | 25.0% | ||
| Q3 25 | -8.0% | 7.5% | ||
| Q2 25 | -4.4% | -0.9% | ||
| Q1 25 | -11.8% | -21.4% | ||
| Q4 24 | -3.8% | 26.3% | ||
| Q3 24 | -11.7% | -1.6% | ||
| Q2 24 | -27.4% | -8.9% | ||
| Q1 24 | -29.4% | -7.5% |
| Q4 25 | $-0.11 | $0.46 | ||
| Q3 25 | $-0.18 | $0.10 | ||
| Q2 25 | $-0.12 | $-0.01 | ||
| Q1 25 | $-0.21 | $-0.23 | ||
| Q4 24 | $-0.11 | $0.40 | ||
| Q3 24 | $-0.31 | $-0.02 | ||
| Q2 24 | $-0.57 | $-0.10 | ||
| Q1 24 | $-0.59 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.5M | $137.5M |
| Total DebtLower is stronger | $185.1M | — |
| Stockholders' EquityBook value | $-18.2M | $354.6M |
| Total Assets | $434.9M | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.5M | $137.5M | ||
| Q3 25 | $8.1M | $135.4M | ||
| Q2 25 | $9.1M | $116.9M | ||
| Q1 25 | $5.9M | $112.9M | ||
| Q4 24 | $12.4M | $116.2M | ||
| Q3 24 | $10.1M | $101.7M | ||
| Q2 24 | $9.3M | $102.5M | ||
| Q1 24 | $7.5M | $110.6M |
| Q4 25 | $185.1M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $202.7M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-18.2M | $354.6M | ||
| Q3 25 | $-12.1M | $321.9M | ||
| Q2 25 | $-7.7M | $306.8M | ||
| Q1 25 | $-8.1M | $295.5M | ||
| Q4 24 | $-4.4M | $292.0M | ||
| Q3 24 | $1.6M | $257.5M | ||
| Q2 24 | $6.5M | $243.0M | ||
| Q1 24 | $18.0M | $233.9M |
| Q4 25 | $434.9M | $488.0M | ||
| Q3 25 | $435.2M | $453.3M | ||
| Q2 25 | $438.1M | $435.6M | ||
| Q1 25 | $441.0M | $424.6M | ||
| Q4 24 | $471.0M | $432.7M | ||
| Q3 24 | $495.7M | $390.4M | ||
| Q2 24 | $494.9M | $376.8M | ||
| Q1 24 | $494.9M | $356.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.3M | $15.0M |
| Free Cash FlowOCF − Capex | $4.1M | $12.8M |
| FCF MarginFCF / Revenue | 8.2% | 13.8% |
| Capex IntensityCapex / Revenue | 0.3% | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $-2.9M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.3M | $15.0M | ||
| Q3 25 | $295.0K | $22.1M | ||
| Q2 25 | $1.6M | $8.2M | ||
| Q1 25 | $-7.7M | $6.6M | ||
| Q4 24 | $8.0M | $22.2M | ||
| Q3 24 | $1.3M | $10.2M | ||
| Q2 24 | $-10.4M | $18.5M | ||
| Q1 24 | $-2.8M | $7.2M |
| Q4 25 | $4.1M | $12.8M | ||
| Q3 25 | $-246.0K | $19.5M | ||
| Q2 25 | $1.2M | $81.0K | ||
| Q1 25 | $-8.0M | $-7.6M | ||
| Q4 24 | $7.0M | $8.5M | ||
| Q3 24 | $-1.1M | $-9.2M | ||
| Q2 24 | $-10.6M | $1.8M | ||
| Q1 24 | $-4.7M | $-6.8M |
| Q4 25 | 8.2% | 13.8% | ||
| Q3 25 | -0.5% | 28.8% | ||
| Q2 25 | 1.9% | 0.1% | ||
| Q1 25 | -19.8% | -14.5% | ||
| Q4 24 | 12.0% | 11.2% | ||
| Q3 24 | -1.8% | -15.9% | ||
| Q2 24 | -22.7% | 3.4% | ||
| Q1 24 | -10.4% | -13.3% |
| Q4 25 | 0.3% | 2.4% | ||
| Q3 25 | 1.0% | 3.9% | ||
| Q2 25 | 0.6% | 12.9% | ||
| Q1 25 | 0.6% | 27.0% | ||
| Q4 24 | 1.7% | 18.3% | ||
| Q3 24 | 4.0% | 33.5% | ||
| Q2 24 | 0.5% | 31.8% | ||
| Q1 24 | 4.3% | 27.3% |
| Q4 25 | — | 0.65× | ||
| Q3 25 | — | 4.35× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.12× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
